Case Reports
6 June 2023
Vol. 15 No. 3 (2023)
Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
759
Views
455
Downloads
17
HTML
Authors
Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.
Altmetrics
Downloads
Download data is not yet available.
Citations
Moro F, Fania L, Sinagra JLM, et al. Bullous pemphigoid: Trigger and predisposing factors. Biomolecules 2020;10:1-29.
Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol 2018;138:1201-4.
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019;10:1-10.
García Castro R, Godoy Gijón E, González Pérez AM, Román Curto C. Bullous pemphigoid and DPP4 inhibitors. Med Clin (Barc) 2019;153:368-71.
Fukuda G, Yoshida T, Hirayama A, et al. Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report. Geriatr Gerontol Int 2019;19:1289-90.
Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Reports 2021;15:107-9.
Collins MK, Choudhary S, Ho J, Bunimovich YL. Bullous pemphigoid triggered by liraglutide. Cutis 2021;107:E9-E11.
How to Cite
Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature. (2023). Dermatology Reports, 15(3). https://doi.org/10.4081/dr.2023.9676
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
